Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company. It focuses on the discovery, development, manufacture and commercialization of pharmaceuticals for various medical conditions. The company offers its products to specialty distributors, wholesalers, hospital pharmacies and specialist physicians in private practice. Genentech also offers patient support services such as co-pay programs, health insurance, and independent co-pay assistance, among others. The company has more than 40 marketed drugs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Genentech undertakes research and development (R&D) initiatives focused on advancing inclusive research to increase representation of historically under-studied and underrepresented patients in clinical research. The company is actively designing studies to gain new insights and build a knowledge base for underrepresented communities, particularly in diseases that disproportionately or differentially affect patients across races, ethnicities, and ancestries. Key inclusive studies include Chimes, Elevatum, and Catori, which focus on diverse patient populations with multiple sclerosis and diabetic macular edema. Genentech also collaborates with external partners, including the External Council for Advancing Inclusive Research and the Advancing Inclusive Research Site Alliance, to strategize on reaching more representative patient populations and to establish best practices for inclusive research. Some of its Phase III pipeline drugs include afimkibart to treat ulcerative colitis and crohn's disease; astegolimab to treat chronic obstructive pulmonary disease; atezolizumab to treat previously untreated metastatic triple negative breast cancer, neoadjuvant triple negative breast cancer, and adjuvant triple negative breast cancer; baloxavir marboxil to treat influenza in children ages 1 and older and reduction of transmission of influenza in households; cobimetinib to treat metastatic melanoma; crovalimab to treat paroxysmal nocturnal hemoglobinuria (PNH); emicizumab to treat hemophilia a; omalizumab to treat food allergies; pertuzumab to treat early her2-positive breast cancer in combination with trastuzumab emtansine; RG6179 to treat uveitic macular edema (UME); tenecteplase to treat acute ischemic stroke (AIS); obinutuzumab to treat systemic lupus erythematosus, lupus nephritis, and food allergies; among others. It has more than 20,000 patents received and 39 FDA breakthrough therapy designations.